A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subjects

Trial Profile

A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Alirocumab (Primary) ; Ezetimibe; Fenofibrate
  • Indications Hypercholesterolaemia
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 06 Jan 2017 Results of a pooled target mediated drug disposition population pharmacokinetics analysis of Alirocumab from this and 12 other studies (n=2870), published in the Clinical Pharmacokinetics.
    • 30 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 06 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top